FE
FEMY.US Femasys Inc
- Market cap
- USD 11.9M
- P/E
- -
- P/B
- 2.91x
- ROE
- -42.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is FEMY.US undervalued?
Graham numberThe Graham number of Femasys Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Femasys Inc fundamental analysis
No fundamental analysis for Femasys Inc yet.
Femasys Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Femasys Inc
Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; and…
Full company profileFemasys Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Femasys Inc annual financial statements
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 929K | 1.04M | 1.18M | 1.21M | 1.07M | 1.63M | 2.29M | 1.55M |
| Gross Profit | 705K | 731K | 809K | 764K | 692K | 1.08M | 1.42M | - |
| Operating Income | -11.6M | -6.93M | -8.34M | -11.6M | -14.5M | -17.8M | -17.6M | -18.3M |
| EBITDA | -10.2M | -5.80M | -6.55M | -10.5M | -13.2M | -16.3M | -15.9M | -9.65M |
| Net Income | -11.3M | -6.91M | -7.54M | -11.4M | -14.2M | -18.8M | -18.6M | -11.6M |
| EPS | -19 | -12 | -13 | -19 | -19 | -17 | -9.42 | -1.34 |
| Balance Sheet | ||||||||
| Total Assets | 12.6M | 7.61M | 28.6M | 16.9M | 27.8M | 12.4M | 20.7M | - |
| Total Liabilities | 58.0M | 4.08M | 2.24M | 1.65M | 9.40M | 10.1M | 14.9M | 4.46M |
| Shareholders' Equity | -45.4M | 3.53M | 26.3M | 15.2M | 18.4M | 2.30M | 5.87M | 27.0M |
| Cash & Short-term Investments | 7.41M | 3.32M | 24.8M | 13.0M | 21.7M | 3.45M | 9.27M | - |
| Total Debt | 1.71M | 2.06M | 990K | 544K | 6.70M | 7.44M | 4.70M | 4.87M |
| Cash Flow | ||||||||
| Operating Cash Flow | -11.0M | -4.93M | -7.93M | -10.7M | -11.3M | -19.4M | -18.7M | -17.2M |
| Capital Expenditure | 696K | 31.7K | 307K | 407K | 144K | 762K | 525K | 141K |
| Free Cash Flow | -11.7M | -4.96M | -8.24M | -11.1M | -11.4M | -20.2M | -19.2M | -17.3M |
| Ratios | ||||||||
| ROE | - | -196.0% | -28.6% | -74.8% | -77.6% | -816.5% | -317.4% | -42.9% |
| ROA | -89.1% | -90.9% | -26.4% | -67.4% | -51.3% | -151.2% | -89.9% | - |
| Net Profit Margin | -1,213.3% | -666.2% | -639.0% | -944.6% | -1,329.1% | -1,155.0% | -812.3% | -749.6% |
| Debt to Equity | - | 0.58x | 0.04x | 0.04x | 0.37x | 3.23x | 0.80x | 0.18x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Femasys Inc dividends
Femasys Inc has not paid dividends in the last 7 fiscal years.
Last stock split: 1:20 on Jun 8, 2026.
Who owns Femasys Inc
- Insiders 4.02%
- Institutions 55.01%
- Public & others 40.97%
- Shares outstanding 8.38M
- Free float 6.88M
Top funds holding FEMY.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 34.3K | 0.41% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 15.0K | 0.18% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 3.94K | 0.05% | 0.00% | Aug 2026 |
| Fidelity Series Total Market Index | 3.83K | 0.05% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 2.61K | 0.03% | 0.00% | Sep 2026 |
Top institutions holding FEMY.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Dauntless Investment Group, LLC | 1.87M | 22.30% | +519.25% | Jun 2026 |
| Vanguard Capital Management, LLC | 62.2K | 0.74% | +0.64% | Jun 2026 |
| Jane Street Group LLC | 52.5K | 0.63% | +3,153.47% | Jun 2026 |
| Geode Capital Management, LLC | 30.9K | 0.37% | -0.48% | Jun 2026 |
| UBS Group AG | 18.8K | 0.22% | +506.49% | Jun 2026 |
| Citadel Advisors Llc | 16.9K | 0.20% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 12.5K | 0.15% | -0.02% | Jun 2026 |
| Advisor Group Holdings, Inc. | 2.40K | 0.03% | -0.04% | Jun 2026 |
| BlackRock Inc | 1.78K | 0.02% | -80.01% | Jun 2026 |
| IFP Advisors, LLC | 1.05K | 0.01% | +2,000.00% | Jun 2026 |
| Northwestern Mutual Wealth Management Co | 1.00K | 0.01% | 0.00% | Jun 2026 |
| SRS Capital Advisors Inc | 900.00 | 0.01% | 0.00% | Jun 2026 |
| WHITTIER TRUST Company of NEVADA Inc | 794.00 | 0.01% | 0.00% | Jun 2026 |
| CX Institutional, LLC | 750.00 | 0.01% | 0.00% | Jun 2026 |
| Trust Co Of Toledo Na | 87.00 | 0.00% | -1.14% | Jun 2026 |
| Barclays PLC | 8.00 | 0.00% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 7.00 | 0.00% | -12.50% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 3.00 | 0.00% | 0.00% | Jun 2026 |
| Kovack Advisors Inc | 0.00 | 0.00% | -100.00% | Jun 2026 |
| State Street Corp | 0.00 | 0.00% | -100.00% | Jun 2026 |
Femasys Inc company profile
- Company name
- Femasys Inc
- Ticker
- FEMY.US
- Exchange
- USA Stocks
- Listed since
- Jun 18, 2021
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 51
- Fiscal year end
- December
- Address
- 3950 Johns Creek Court, Suwanee, GA, United States, 30024
- Phone
- 770 500 3910
- Website
- femasys.com
About Femasys Inc
Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; and FemCath, a cornual balloon catheter for selective tube evaluation. It also provides FemBloc, a non-surgical female permanent birth control solution. The company offers its products to gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.
Femasys Inc management
6- Ms. Kathy Lee-Sepsick M.B.A.Founder, President, CEO & Director · born 1968
- Mr. Dov ElefantChief Financial Officer · born 1967
- Mr. John CanningChief Operating Officer · born 1974
- Mr. Jeremy Alexander Sipos M.S.Chief Technology Officer · born 1974
- Dr. James H. Liu M.D.Chief Medical Officer
- Dr. Jeffrey Gerald MifekChief Clinical & Regulatory Affairs Officer